| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f0c665eb6c97ca102d7531ada462b06d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4737
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-102
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16C20-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16C20-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B25-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B40-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-00 |
| filingDate |
2018-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db7761d7dd76534b3a48d56374ba716f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6db87174232a1cf24d44a204c1395b91
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b35d8350c4bc7b15f97f2ce128a01370
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e94dd0a3e265a2a5e5de30c4929faa2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79d621018897e85df9a194d76b09720c |
| publicationDate |
2020-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3698143-A1 |
| titleOfInvention |
Method for estimating the effectiveness against rheumatoid arthritis of a co-stimulation modulator of t-lymphocytes |
| abstract |
The present invention relates to a method for estimating the efficacy of treatment with a T-cell co-stimulatory modulatory agent in a patient with rheumatoid arthritis who has been in inadequate response to at least one prior biologic therapy, analyzing a biological sample of said patient for the expression of a set of biomarkers, the results of which make it possible to determine whether said agent is a treatment that will generate a beneficial response for said patient. The present invention also relates to a system for estimating the efficacy of said treatment in said patient comprising means for measuring or receiving the data, the level of expression of said biomarkers and means for processing these data configured to estimate said efficiency. said treatment in said patient. The biomarkers comprise at least two biomarkers selected from the group consisting of C4b-binding protein (C4BP), C-reactive protein (CRP), cartilage oligomeric matrix protein (COMP), fibronectin (FN) and lipopolysaccharide-binding protein (LBP). |
| priorityDate |
2017-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |